31.10SEK-6.04%Mkt Cap: 2.05B SEKP/E: —Last update: 2026-06-01
BioInvent International AB (publ), a clinical-stage company, discovers and develops immuno-modulatory antibodies for cancer therapy in Sweden, Europe, the United States, and internationally. The company's drug candidates…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap2.05B SEK
Enterprise Value1.73B SEK
Revenue (TTM)217.86M SEK
Gross Profit217.86M SEK
Net Income (TTM)-332.86M SEK
Revenue/Share3.311 SEK
Last Price31.10 SEK
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees112
CountrySE
SectorHealthcare
IndustryBiotechnology
ISINSE0015244520
Valuation
P/E (Trailing)—
P/E (Forward)-8.42
PEG0.27
EV/EBITDA-5.10
EV/Revenue7.93
P/S10.00
P/B4.96
EPS (TTM)-5.10
EPS (Forward)-3.93
52W Range
20.8549% of range41.60
52W High41.60 SEK
52W Low20.85 SEK
Profitability
Gross Margin100.00%
Oper. Margin-907.23%
EBITDA Margin-155.52%
Profit Margin-146.96%
ROE-59.69%
ROA-49.59%
Growth
Revenue Growth-39.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF-247.75M SEK
CapEx (TTM)7.26M SEK
FCF Margin-73.63%
FCF Yield-7.84%
Net Debt-450.22M SEK
Net Debt/EBITDA1.33
Balance Sheet
Debt/Equity0.02
Current Ratio5.32
Quick Ratio5.20
Book Value/Sh6.673 SEK
Cash/Share6.937 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:25
Split DateDec 14, 2020
Analyst Consensus
Rating1.5 (Buy)
Target (Mean)95.00 SEK
Target Range85.00 SEK – 110.00 SEK
# Analysts3
Ownership
Shares Out.65.80M
Float31.44M
Insiders10.17%
Institutions57.12%
Technical
SMA 5023.58 (+31.9%)
SMA 20027.31 (+13.9%)
Beta-0.05
S&P 52W Chg27.70%
Avg Vol (30d)160.24K
Avg Vol (10d)263.30K
Technical Indicators
RSI (14)79.1
MACD2.3791
MACD Signal1.3428
MACD Hist.+1.0364
BB Upper32.94 SEK
BB Middle25.32 SEK
BB Lower17.70 SEK
BB Width60.17%
ATR (14)1.725 SEK
Vol Ratio (20d)1.26x